Oncolytics Biotech (ONCY)

• Market cap: $44.9M
• 1 day: -3.00%
• 5 days: 1.57%
• 1 month: -12.20%
• 3 months: -32.48%
• 6 months: -48.71%
• Year to date: -44.29%
• 1 year: -56.10%
• 5 years: -74.36%
• 10 years: -91.73%
• Sector: Healthcare
• Industry: Biotechnology

About: Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.

Employees: 28

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

100% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 7

67% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 6

10% more capital invested

Capital invested by funds: $1.1M [Q3] → $1.21M (+$107K) [Q4]

10% more funds holding

Funds holding: 42 [Q3] → 46 (+4) [Q4]

0.15% more ownership

Funds ownership: 1.55% [Q3] → 1.71% (+0.15%) [Q4]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $3 479% upside
• Avg. target: $4.33 737% upside
• High target: $5 865% upside

3 analyst ratings

• positive: 3 100%
• neutral: 0 0%
• negative: 0 0%

Maxim Group Jason McCarthy 19% 1-year accuracy 6 / 31 met price target	479% upside $3	Buy Maintained	10 Mar 2025
HC Wainwright & Co. Patrick Trucchio 24% 1-year accuracy 43 / 177 met price target	865% upside $5	Buy Reiterated	10 Mar 2025
RBC Capital Douglas Miehm 42% 1-year accuracy 10 / 24 met price target	865% upside $5	Outperform Maintained	10 Mar 2025